In addition, GBP1 is linked to radiotherapy resistance in head and neck tumors [23] and is a component of the cytoskeletal gateway of drug resistance in ovarian cancer [21, 22], especially for paclitaxel, which is a common therapeutic choice for treating TNBC [88]. The gene discussed is GBP1; the disease is head and neck neoplasm.